Information Provided By:
Fly News Breaks for February 1, 2016
MYL, TEVA
Feb 1, 2016 | 08:04 EDT
After Novartis (NVS) reported weak results for its generics unit, Sandoz, and blamed it on industry trends, Bernstein quotes Mylan (MYL) and Teva (TEVA) as saying that they are seeing only "slight adjustments back to normal levels" from "mildly favorable" results in 2014 and 2015. Bernstein says that Sandoz has lost a number of fairly profitable products and has had fewer approvals than its peers. Bernstein keeps Outperform ratings on Teva and Mylan.
News For TEVA;MYL From the Last 2 Days
There are no results for your query TEVA;MYL